Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

It's natural for your vision to shift over time. Here are simple ways to care for your eyes, especially this bright, sunny ...

BY CASSIUS LAMAI The Chairman of Etsako Central Local Government Area, Hon. Cephas Yakubu, in partnership with the Edo State government has flagged off a three-day free eye care initiative in ...

Lutein and zeaxanthin are carotenoids — natural pigments that are responsible for giving fruits and vegetables their red, yellow or orange hue. Carotenoids also act as antioxidants, helping to filter ...

In addition to a strong lineup of presenters, Doheny will also be well represented as SriniVas R. Sadda, MD, closes out his term as president of ARVO at the culmination of the 2025 meeting. Dr. Sadda ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon ...

Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

Adverum Biotechnologies, Inc.’s ADVM share price has surged by 7.87%, which has investors questioning if this is right time to sell.